Cargando…
An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years
New molecular mechanisms that can be targeted with specific drugs have recently emerged for the treatment of systemic sclerosis (SSc) patients. Over the past 3 years, the achievement of one large phase 3 trial has led to the approval by drug agencies of the first drug licenced for SSc-related inters...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168022/ https://www.ncbi.nlm.nih.gov/pubmed/34074331 http://dx.doi.org/10.1186/s13075-021-02536-5 |